Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
9 Leser
Artikel bewerten:
(0)

Elsevier to Market Stanson Health CDS System, Complementing Elsevier's Broad Portfolio of Clinical Workflow Solutions

PHILADELPHIA, April 23, 2014 /PRNewswire/ --

Stanson's next-generation clinical decision support and analytics solution fully integrates into EMRs, provides alerts to help providers keep care costs low, quality high

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today an agreement to market Stanson Health's next-generation clinical decision support (CDS) and analytics solution. Stanson's CDS solutions are designed to safely reduce the cost and potential for harm from unnecessary care by leveraging user-friendly, real-time alerts and analytics to help guide physicians' decisions.

Stanson's CDS solutions complement the Elsevier Clinical Solutions suite, which includes a portfolio of solutions for workflow and decision support, clinical reference and drug reference, patient engagement and performance management.

As the healthcare industry evolves, healthcare payers (i.e., insurance companies, the government) are counting on physicians and hospitals to control and even reduce costs as they improve the quality of care. Unnecessary or inappropriate care accounts for a significant amount of the overall healthcare spend, and more than 80 percent of overall healthcare costs are directly linked to decisions made by physicians.

Stanson Health, a population health, CDS and analytics company, provides previously tested and validated CDS alerts, which reduce the potential for "false positive" alerts that cause alert fatigue. The alerts are designed to reduce unnecessary care for patient populations across the continuum, in physician offices, emergency departments and hospitals. The CDS recommendations are based on widely accepted guidelines, including from Choosing Wisely®, an initiative of the ABIM Foundation. The analytics solution provides comparative information on physician acceptance and rejection of CDS recommendations and provides "utilization fingerprints" that are used to inform discussions about high quality and cost-effective care.

"With the transition toward population health and payment reform, and the improvement in EHR functionality, we believe that there is need for the next generation of CDS," said Scott Weingarten, MD, Chairman of Stanson Health. "The CDS should be integrated into the workflow, personalized for each patient, accompanied by analytics and tested prior to release to reduce false-positives, impact care across the continuum, safely reduce costs and improve quality."

Weingarten was the co-founder and CEO of Zynx Health for 16 years. Stanson Health's CDS and analytics solution was first implemented at Cedars-Sinai Health System, where it demonstrated statistically significant improvements in the quality of patient care and reductions in inappropriate care.

For example, with Stanson Health, a physician can compare how often he or she accepts and rejects Choosing Wisely guidelines related to performing CT scans for patients with chronic isolated headache with other physicians at that organization. This information can be very useful as physician organizations prepare for health care reform, ACOs, risk-based payments, exchanges, and narrow networks.

"By providing a CDS alert system to physicians at the point of decision, we hope to enable physicians to make more valuable clinical decisions that are based on evidence and help reduce unnecessary and costly care," said Jay Katzen, President of Elsevier Clinical Solutions. "This CDS tool is a great complement to our portfolio of workflow solutions delivering order sets, care planning and documentation, and drug decision support. Based on the positive reviews from the physicians who trialed the Stanson product, we expect to take a significant step forward in helping our customers improve care and reduce costs with this CDS tool."

For more information about Stanson Health CDS alerts and analytics from Elsevier, please contact us at CDSAlerts@elsevier.com.

---

About Stanson Health

Headquartered in Los Angeles, CA, Stanson Health LLC is leading the way inthedevelopment ofthenext generation CDS solutions. Stanson provides integrated real time alerts optimized for use in the physician's clinical workflow. Combined with relevant analytics, Stanson solutions safely guide physician's decisions toward the elimination of unnecessary or inappropriate careand helps improve the quality of care.Health care systems and organizations preparing forpayment reformand population healthrecognizethatStanson Health solutions deliver the most effective cost reducing CDS available today. To learn more, visitstansonhealth.com or call+1 310 444 7179.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier providesweb-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Christopher Capot
Director, Corporate Relations
Elsevier
+1-212-633-3164
c.capot@elsevier.com


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.